3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
7
Recruiting
3
Terminated
2
Withdrawn
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
5
Plasma cell
2
Other hematologic neoplasm
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Interventions
Oxaliplatin
86
Bevacizumab
66
Capecitabine
65
Fluorouracil
48
tislelizumab
41
Gemcitabine
40
Drug Therapy
39
Leucovorin
38
sintilimab
35
Irinotecan
34
lenvatinib
27
Cisplatin
27
HMPL-013
25
S 1 (combination)
23
camrelizumab
22
Immune Checkpoint Inhibitors
21
irinotecan sucrosofate
20
apatinib
20
Surgical Procedures, Operative
20
Radiotherapy
20
Injections
20
130-nm albumin-bound paclitaxel
20
toripalimab
19
Paclitaxel
18
Folfox protocol
17
pembrolizumab
15
Immunotherapy
15
Cetuximab
15
Specimen Handling
14
regorafenib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Immunotherapy, Adoptive
×
Gastrointestinal
×
Clear all
NCT07153289
2025-09-03
ResCPa
University Hospital Tuebingen
Phase 1/2
Not yet recruiting
38 enrolled